Abeona therapeutics appoints madhav vasanthavada, ph.d., m.b.a. as chief commercial officer

Cleveland, sept. 12, 2023 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced the appointment of madhav vasanthavada, ph.d., m.b.a. to the role of chief commercial officer (cco) and head of business development (bd), effective immediately. in this capacity, in addition to his current bd responsibilities, dr. vasanthavada will oversee all aspects of commercial strategy, planning and operations as abeona prepares for a potential launch of eb-101, its investigational, genetically engineered autologous cell therapy for recessive dystrophic epidermolysis bullosa (rdeb). dr. vasanthavada is a seasoned commercial executive bringing over 20 years of experience with leadership roles in sales, marketing, and market access in the life sciences industry, including launch experience with autologous cell therapies. over the past year, as abeona's head of bd, dr. vasanthavada's efforts to assess eb-101's commercial opportunity informed the company's strategy to prepare for a u.s. commercial launch without depending on a partner.
ABEO Ratings Summary
ABEO Quant Ranking